SG11202108770TA - Combination therapy for treatment of b-cell malignancies - Google Patents

Combination therapy for treatment of b-cell malignancies

Info

Publication number
SG11202108770TA
SG11202108770TA SG11202108770TA SG11202108770TA SG11202108770TA SG 11202108770T A SG11202108770T A SG 11202108770TA SG 11202108770T A SG11202108770T A SG 11202108770TA SG 11202108770T A SG11202108770T A SG 11202108770TA SG 11202108770T A SG11202108770T A SG 11202108770TA
Authority
SG
Singapore
Prior art keywords
treatment
combination therapy
cell malignancies
malignancies
cell
Prior art date
Application number
SG11202108770TA
Inventor
Sriram Balasubramanian
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11202108770TA publication Critical patent/SG11202108770TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
SG11202108770TA 2019-02-15 2020-02-14 Combination therapy for treatment of b-cell malignancies SG11202108770TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806148P 2019-02-15 2019-02-15
PCT/IB2020/051270 WO2020165861A1 (en) 2019-02-15 2020-02-14 Combination therapy for treatment of b-cell malignancies

Publications (1)

Publication Number Publication Date
SG11202108770TA true SG11202108770TA (en) 2021-09-29

Family

ID=69740437

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108770TA SG11202108770TA (en) 2019-02-15 2020-02-14 Combination therapy for treatment of b-cell malignancies

Country Status (14)

Country Link
US (1) US20200262925A1 (en)
EP (1) EP3923945A1 (en)
JP (1) JP2022520429A (en)
KR (1) KR20210129111A (en)
CN (1) CN113766918A (en)
AU (1) AU2020222359A1 (en)
CA (1) CA3129593A1 (en)
EA (1) EA202192256A1 (en)
IL (1) IL285458A (en)
JO (1) JOP20210225A1 (en)
MA (1) MA54941A (en)
MX (1) MX2021009821A (en)
SG (1) SG11202108770TA (en)
WO (1) WO2020165861A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983670A4 (en) * 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
KR20160066554A (en) * 2013-10-25 2016-06-10 파마싸이클릭스 엘엘씨 Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
RS63364B1 (en) * 2014-08-11 2022-07-29 Acerta Pharma Bv Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
WO2016128912A1 (en) * 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
JP6944936B2 (en) * 2015-12-04 2021-10-06 ポートラ ファーマシューティカルズ, インコーポレイテッド Serduratinib for treating blood cancer
TWI739887B (en) * 2016-08-19 2021-09-21 英屬開曼群島商百濟神州有限公司 Treatment cancers using a combination comprising btk inhibitors

Also Published As

Publication number Publication date
KR20210129111A (en) 2021-10-27
EP3923945A1 (en) 2021-12-22
CN113766918A (en) 2021-12-07
MX2021009821A (en) 2021-11-12
IL285458A (en) 2021-09-30
JOP20210225A1 (en) 2023-01-30
WO2020165861A1 (en) 2020-08-20
EA202192256A1 (en) 2021-10-27
MA54941A (en) 2021-12-22
AU2020222359A1 (en) 2021-09-02
US20200262925A1 (en) 2020-08-20
JP2022520429A (en) 2022-03-30
CA3129593A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
IL281256A (en) Combination therapy for the treatment of triple-negative breast cancer
IL276398A (en) Combination therapy for the treatment of mastocytosis
IL267795A (en) Combination therapy for the treatment of cancer
IL292810A (en) Therapeutic compounds and methods of use
ZA202206743B (en) Therapy for the treatment of cancer
IL280337A (en) Lag-3 combination therapy for the treatment of cancer
IL281845A (en) Combination therapy for the treatment of cancer
IL285155A (en) Metal chelator combination therapy for the treatment of cancer
SG11202011117VA (en) Treatment of cancer
EP4010081A4 (en) Combination therapy for treatment of cancer
IL284162A (en) Combination therapy for the treatment of cancer
IL282643A (en) Combination therapy for treatment of hematological diseases
IL279591A (en) Methods of treating cancer using combination therapy
GB2587172B (en) Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer
IL266993A (en) Combination therapy for the treatment of cancer
IL281997A (en) Combination therapy for the treatment of uveal melanoma
GB201800736D0 (en) Combination therapy for treatment of leukemia
IL281281A (en) Combination therapy for the treatment of prostate cancer
EP4110344A4 (en) Use of thyromimetics for the treatment of cancer
EP4037761C0 (en) Device for radiotherapy treatment of cancer patients
IL289201A (en) Compounds for treatment of cancer
IL286353A (en) Combinations of iadademstat for cancer therapy
IL285458A (en) Combination therapy for treatment of b-cell malignancies
IL263905A (en) Combination therapy of cancer
IL253642A0 (en) Combination therapy for the treatment of cancer